242 related articles for article (PubMed ID: 33969651)
21. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
Mondal D; Kumar A; Sharma A; Ahmed MM; Hasnain MG; Alim A; Huda MM; Rahman R; Alvar J; Ahmed BN; Haque R
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007653. PubMed ID: 31415565
[TBL] [Abstract][Full Text] [Related]
22. To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL).
Rabi Das VN; Siddiqui NA; Pal B; Lal CS; Verma N; Kumar A; Verma RB; Kumar D; Das P; Pandey K
PLoS One; 2017; 12(3):e0174497. PubMed ID: 28355259
[TBL] [Abstract][Full Text] [Related]
23. Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh.
Islam S; Kenah E; Bhuiyan MA; Rahman KM; Goodhew B; Ghalib CM; Zahid MM; Ozaki M; Rahman MW; Haque R; Luby SP; Maguire JH; Martin D; Bern C
Am J Trop Med Hyg; 2013 Aug; 89(2):345-53. PubMed ID: 23817330
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of blood based quantitative PCR as a molecular diagnostic tool for post kala-azar dermal leishmaniasis (PKDL).
Kumar A; Singh VK; Madhukar P; Tiwari R; Roy R; Rajneesh ; Mehrotra S; Sundar S; Kumar R
Mol Biol Rep; 2024 Jun; 51(1):716. PubMed ID: 38824237
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report.
Ramesh V; Avishek K; Sharma V; Salotra P
Acta Derm Venereol; 2014 Mar; 94(2):242-3. PubMed ID: 23995012
[No Abstract] [Full Text] [Related]
26. Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India.
Das VN; Ranjan A; Pandey K; Singh D; Verma N; Das S; Lal CS; Sinha NK; Verma RB; Siddiqui NA; Das P
Am J Trop Med Hyg; 2012 Jun; 86(6):959-61. PubMed ID: 22665600
[TBL] [Abstract][Full Text] [Related]
27. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
[TBL] [Abstract][Full Text] [Related]
28. A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh.
Sundar S; Pandey K; Mondal D; Madhukar M; Kamal Topno R; Kumar A; Kumar V; Kumar Verma D; Chakravarty J; Chaubey R; Kumari P; Rashid MU; Maruf S; Ghosh P; Raja S; Rode J; den Boer M; Das P; Alvar J; Rijal S; Alves F
PLoS Negl Trop Dis; 2024 Jun; 18(6):e0012242. PubMed ID: 38900786
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Recombinase Polymerase Amplification assay for monitoring parasite load in patients with kala-azar and post kala-azar dermal leishmaniasis.
Roy M; Ceruti A; Kobialka RM; Roy S; Sarkar D; Wahed AAE; Chatterjee M
PLoS Negl Trop Dis; 2023 Apr; 17(4):e0011231. PubMed ID: 37075066
[TBL] [Abstract][Full Text] [Related]
30. Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform.
Singh-Phulgenda S; Kumar R; Dahal P; Munir A; Rashan S; Chhajed R; Naylor C; Maguire BJ; Siddiqui NA; Harriss E; Rahi M; Alves F; Sundar S; Stepniewska K; Musa A; Guerin PJ; Pandey K
PLoS Negl Trop Dis; 2024 Apr; 18(4):e0011635. PubMed ID: 38626228
[TBL] [Abstract][Full Text] [Related]
31. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
32. PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India.
Ganguly S; Saha P; Chatterjee M; Roy S; Ghosh TK; Guha SK; Kundu PK; Bera DK; Basu N; Maji AK
PLoS Negl Trop Dis; 2015; 9(10):e0004138. PubMed ID: 26485704
[TBL] [Abstract][Full Text] [Related]
33. Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine.
Salam MA; Siddiqui MA; Nabi SG; Bhaskar KR; Mondal D
J Health Popul Nutr; 2013 Jun; 31(2):294-7. PubMed ID: 23930349
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
35. Active surveillance identified a neglected burden of macular cases of Post Kala-azar Dermal Leishmaniasis in West Bengal.
Sengupta R; Chaudhuri SJ; Moulik S; Ghosh MK; Saha B; Das NK; Chatterjee M
PLoS Negl Trop Dis; 2019 Mar; 13(3):e0007249. PubMed ID: 30856178
[TBL] [Abstract][Full Text] [Related]
36. Case Report: An Atypical Case of Post-Kala-Azar Dermal Leishmaniasis with Ulcers and Verrucous Lesions: Clinical and Therapeutic Implications.
Mathachan SR; Khurana A; Bansal A; Singhai M; Kumari R; Sardana K; Sood V; Khatri P; Singh I
Am J Trop Med Hyg; 2024 Jan; 110(1):40-43. PubMed ID: 38011733
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study.
Singh S ; Kumar J; Singh R; Dwivedi SN
Int J Infect Dis; 2000; 4(4):203-8. PubMed ID: 11231183
[TBL] [Abstract][Full Text] [Related]
38. Post kala-azar dermal leishmaniasis: macular variety.
Das A; Sarkar TK
Indian Pediatr; 2014 Dec; 51(12):1041. PubMed ID: 25560172
[No Abstract] [Full Text] [Related]
39. Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL).
Wijnant GJ; Moulik S; Chatterjee K; Das NK; de la Flor R; Van Bocxlaer K; Croft SL; Chatterjee M
Exp Parasitol; 2024 Feb; 257():108687. PubMed ID: 38114040
[TBL] [Abstract][Full Text] [Related]
40. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
